Resmetirom NEW
| Price | $33 | $33 | $33 | $47 | $47 | $47 | $89 | $89 | $89 |
| Package | 1mg | 1mg | 1mg | 2mg | 2mg | 2mg | 5mg | 5mg | 5mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Resmetirom | CAS No.: 920509-32-6 |
| Purity: 99.91% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Resmetirom |
| Description | Resmetirom (VIA-3196) is a highly selective thyroid hormone receptor β (THR-β) agonist. |
| In vitro | Resmetiromis 28-fold selective for THR-β (EC50=0.21 μM) over THR-α (EC50=3.74 μM ) in a functional assay. Resmetiromshows an IC20 of roughly 30 μM for blockage of the hERG channel. The IC50 for CYP3A4/5 and for CYP2C19 is >50 μM, and there is only weak inhibition (roughly 22 μM) of CYP2C9[1]. |
| In vivo | MGL-3196 demonstrates favorable exposures and acceptable oral bioavailability in rats, with both the volume of distribution and clearance being low. When administered orally to DIO mice, MGL-3196 in a suspension form shows dose-dependent increases in exposure[1]. Treatment with MGL-3196 leads to decreased cholesterol levels and liver size, attributed to the reduction of liver triglycerides (TG). Importantly, no impact is observed on bone mineral density (BMD), or the size of the heart or kidneys in animals receiving MGL-3196[1]. |
| Storage | store at low temperature,store under nitrogen | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/mL (137.86 mM) |
| Keywords | Inhibitor | MGL-3196 | Thyroid Hormone Receptor | MGL 3196 | Resmetirom | VIA 3196 | THR | inhibit | VIA3196 |
| Inhibitors Related | Propylthiouracil | Liothyronine | L-Thyroxine | L-Thyroxine sodium | 2,2-BIS(2-HYDROXY-5-BIPHENYLYL)PROPANE | DS08210767 | Carbimazole | Methimazole | Liothyronine sodium | 2-Thiouracil | PCO371 | Tiratricol |
| Related Compound Libraries | Nuclear Receptor Compound Library | Bioactive Compound Library | Drug Repurposing Compound Library | Anti-Cardiovascular Disease Compound Library | Endocrinology-Hormone Compound Library | Orally Active Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Infection Compound Library | Anti-COVID-19 Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2025-01-07 | |
| $0.00/1KG |
VIP2Y
|
Chengdu Aupone Pharmaceutical Co.Ltd.
|
2024-08-30 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-07-23 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY